File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Probiotic supplementation reduces a biomarker for increased risk of liver cancer in young men from Southern China

TitleProbiotic supplementation reduces a biomarker for increased risk of liver cancer in young men from Southern China
Authors
KeywordsAflatoxin B 1-N 7- Guanine
Aflatoxins
Liver Cancer
Probiotic Bacteria
Supplementation
Young Men
Issue Date2006
PublisherAmerican Society for Nutrition. The Journal's web site is located at http://www.ajcn.org/
Citation
American Journal Of Clinical Nutrition, 2006, v. 83 n. 5, p. 1199-1203 How to Cite?
AbstractBackground: In vitro and in vivo studies suggest that selected strains of probiotic bacteria can form tight complexes with aflatoxin B 1 and other carcinogens. Objective: The aim of the present study was to determine whether administration of probiotic bacteria could block the intestinal absorption of aflatoxin B 1 and thereby lead to reduced urinary excretion of aflatoxin B 1-N 7-guanine (AFB-N 7-guanine), a marker for a biologically effective dose of aflatoxin exposure. Elevated urinary excretion of this aflatoxin-DNA adduct is associated with an increased risk of liver cancer. Design: Ninety healthy young men from Guangzhou, China, were randomly assigned to 2 groups; one group received a mixture of Lactobacillus rhamnosus LC705 and Propionibacterium freudenreichii subsp. shermanii strains 2 times/d for 5 wk, and the other group received a placebo preparation. The subjects provided 4 urine samples: at baseline, at 3 and 5 wk after starting the supplementation, and at the end of the 5-wk postintervention period. Results: The percentage of samples with negative AFB-N 7-guanine values tended to be higher in the probiotic group than in the placebo group during the 5-wk intervention period (odds ratio: 2.63, P = 0.052), and a statistically significant decrease in the concentration of urinary AFB-N 7-guanine was observed in the probiotic group. The reduction was 36% at week 3 and 55% at week 5. The geometric means for the probiotic and placebo groups were 0.24 and 0.49 ng AFB-N 7-guanine/mL, respectively, during the intervention period (P = 0.005). Conclusion: A probiotic supplement reduces the biologically effective dose of aflatoxin exposure and may thereby offer an effective dietary approach to decrease the risk of liver cancer. © 2006 American Society for Nutrition.
Persistent Identifierhttp://hdl.handle.net/10722/178943
ISSN
2015 Impact Factor: 6.703
2015 SCImago Journal Rankings: 3.771
References

 

DC FieldValueLanguage
dc.contributor.authorElNezami, HSen_US
dc.contributor.authorPolychronaki, NNen_US
dc.contributor.authorMa, Jen_US
dc.contributor.authorZhu, Hen_US
dc.contributor.authorLing, Wen_US
dc.contributor.authorSalminen, EKen_US
dc.contributor.authorJuvonen, ROen_US
dc.contributor.authorSalminen, SJen_US
dc.contributor.authorPoussa, Ten_US
dc.contributor.authorMykkänen, HMen_US
dc.date.accessioned2012-12-19T09:50:55Z-
dc.date.available2012-12-19T09:50:55Z-
dc.date.issued2006en_US
dc.identifier.citationAmerican Journal Of Clinical Nutrition, 2006, v. 83 n. 5, p. 1199-1203en_US
dc.identifier.issn0002-9165en_US
dc.identifier.urihttp://hdl.handle.net/10722/178943-
dc.description.abstractBackground: In vitro and in vivo studies suggest that selected strains of probiotic bacteria can form tight complexes with aflatoxin B 1 and other carcinogens. Objective: The aim of the present study was to determine whether administration of probiotic bacteria could block the intestinal absorption of aflatoxin B 1 and thereby lead to reduced urinary excretion of aflatoxin B 1-N 7-guanine (AFB-N 7-guanine), a marker for a biologically effective dose of aflatoxin exposure. Elevated urinary excretion of this aflatoxin-DNA adduct is associated with an increased risk of liver cancer. Design: Ninety healthy young men from Guangzhou, China, were randomly assigned to 2 groups; one group received a mixture of Lactobacillus rhamnosus LC705 and Propionibacterium freudenreichii subsp. shermanii strains 2 times/d for 5 wk, and the other group received a placebo preparation. The subjects provided 4 urine samples: at baseline, at 3 and 5 wk after starting the supplementation, and at the end of the 5-wk postintervention period. Results: The percentage of samples with negative AFB-N 7-guanine values tended to be higher in the probiotic group than in the placebo group during the 5-wk intervention period (odds ratio: 2.63, P = 0.052), and a statistically significant decrease in the concentration of urinary AFB-N 7-guanine was observed in the probiotic group. The reduction was 36% at week 3 and 55% at week 5. The geometric means for the probiotic and placebo groups were 0.24 and 0.49 ng AFB-N 7-guanine/mL, respectively, during the intervention period (P = 0.005). Conclusion: A probiotic supplement reduces the biologically effective dose of aflatoxin exposure and may thereby offer an effective dietary approach to decrease the risk of liver cancer. © 2006 American Society for Nutrition.en_US
dc.languageengen_US
dc.publisherAmerican Society for Nutrition. The Journal's web site is located at http://www.ajcn.org/en_US
dc.relation.ispartofAmerican Journal of Clinical Nutritionen_US
dc.subjectAflatoxin B 1-N 7- Guanineen_US
dc.subjectAflatoxinsen_US
dc.subjectLiver Canceren_US
dc.subjectProbiotic Bacteriaen_US
dc.subjectSupplementationen_US
dc.subjectYoung Menen_US
dc.titleProbiotic supplementation reduces a biomarker for increased risk of liver cancer in young men from Southern Chinaen_US
dc.typeArticleen_US
dc.identifier.emailElNezami, HS: elnezami@hkucc.hku.hken_US
dc.identifier.authorityElNezami, HS=rp00694en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.scopuseid_2-s2.0-33745172487en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33745172487&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume83en_US
dc.identifier.issue5en_US
dc.identifier.spage1199en_US
dc.identifier.epage1203en_US
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridElNezami, HS=6603690577en_US
dc.identifier.scopusauthoridPolychronaki, NN=6505944468en_US
dc.identifier.scopusauthoridMa, J=36079484000en_US
dc.identifier.scopusauthoridZhu, H=9237388600en_US
dc.identifier.scopusauthoridLing, W=14054110400en_US
dc.identifier.scopusauthoridSalminen, EK=7006341181en_US
dc.identifier.scopusauthoridJuvonen, RO=7005331813en_US
dc.identifier.scopusauthoridSalminen, SJ=7102912002en_US
dc.identifier.scopusauthoridPoussa, T=6701796915en_US
dc.identifier.scopusauthoridMykkänen, HM=7003915985en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats